CNS Pharmaceuticals, Inc.
CNSP- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001729427
In the last 90 days, CNS Pharmaceuticals, Inc. insiders filed 1 open-market purchase and 0 sales; 11 institutions reported holding it in 13F filings for Q2 2026, worth $1.34M in total; no superinvestor holds it.
Q4 2023 vs. Q3 2023
How the institutions holding CNS Pharmaceuticals, Inc. changed between Q3 2023 and Q4 2023.
All holders in Q4 2023All holders in Q3 2023
| Measure | Q3 2023 | Q4 2023 | Change |
|---|---|---|---|
| Holders | 12 | 16 | +4 |
| Shares | 116.7K | 335.3K | +218.6K (+187.3%) |
| Value | $131.7K | $425.3K | +$293.7K (+223.0%) |
New holders (6)
Institutions that held CNS Pharmaceuticals, Inc. at the end of Q4 2023 but not at the end of Q3 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Armistice Capital, LLC | 122,000 | $154.9K | 0.00% |
| Smith Anglin Financial, LLC | 50,000 | $63.5K | 0.01% |
| Virtu Financial LLC | 13,152 | $17.0K | 0.00% |
| Renaissance Technologies LLC | 11,144 | $14.0K | 0.00% |
| XTX Topco Ltd | 10,002 | $12.6K | 0.00% |
| FMR LLC | 212 | $267 | 0.00% |
Sold out (2)
Institutions that held CNS Pharmaceuticals, Inc. at the end of Q3 2023 and filed for Q4 2023 without it.
| Institution | Shares, Q3 2023 | Value, Q3 2023 |
|---|---|---|
| Susquehanna International Group, LLP | 21,428 | $24.0K |
| UBS Group AG | 55 | $63 |